Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease

Barbara Nuvoli, Sabrina Germoni, Carlotta Morosetti, Raffaela Santoro, Giancarlo Cortese, Serena Masi, Iole Cordone, Rossella Galati

Research output: Contribution to journalArticle

Abstract

Background: Recent evidence suggests that aromatase may be involved in the pathogenesis of malignant mesothelioma. Here, we evaluated the effect of exemestane, an inhibitor of aromatase, in the treatment of mesothelioma using in vitro and in vivo preclinical models.Results: We show a significant reduction of cell proliferation, survival, migration and block of cells in S phase of cell cycle in mesothelioma cells upon exemestane treatment. Moreover, we find that CD44, which is involved in mesothelioma cells migration, was modulated by exemestane via cAMP and pCREB. Most importantly, in mice mesothelioma xenograft exemestane causes a significant decrease in tumor size and the association pemetrexed/exemestane is more effective than pemetrexed/cisplatin.Conclusion: The preclinical mesothelioma model suggests that exemestane might be beneficial in mesothelioma treatment.

Original languageEnglish
Article number69
JournalMolecular Cancer
Volume13
Issue number1
DOIs
Publication statusPublished - Mar 21 2014

Keywords

  • Aromatase
  • Exemestane
  • Mesothelioma

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease'. Together they form a unique fingerprint.

Cite this